A combination of demographic factors with APOE4 status and blood biomarkers, such as GFAP and NfL, might offer a reliable differentiation between healthy controls and patients with an objective cognitive decline, particularly between healthy controls and patients with AD. This evidence concerns the gene GFAP and Alzheimer disease.